drugset / Trial / NCT00363844

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

NCT00363844

Phase 3 Completed 209 enrolled Ono Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy

Timeline

Start
2006-08
Primary completion
2008-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 50 mg
Subject Sitagliptin Small molecule 100 mg